Andere Sprachen Repare Therapeutics Inc.

Aktien

A2P7AV

US7602731025

RPTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 15:36:10 08.05.2024			% 5 Tage	% 1. Jan.
3,74 ^USD	+14,02 %		+5,81 %	-55,07 %

07.05.	Repare Therapeutics Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI
30.04.	Debiopharm & Repare Therapeutics geben die Verabreichung des ersten Patienten in der Phase 1/1B Mythic-Studie bekannt, in der die synthetische tödliche Kombination aus Wee1- und Pkmyt1-Hemmung untersucht wird	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue	14:01
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results	07.05.
Repare Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
DEBIOPHARM AND REPARE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/1B MYTHIC TRIAL EVALUATING THE SYNTHETIC LETHAL COMBINATION OF WEE1 AND PKMYT1 INHIBITION	01.05.
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition	30.04.
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition	30.04.
DEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT D’UN PREMIER PATIENT DANS LE CADRE DE L’ÉTUDE DE PHASE 1/1B MYTHIC ÉVALUANT LA COMBINATION D’INHIBITEURS WEE1 ET PKMYT1 GÉNÉRANT UNE LÉTHALITÉ SYNTHÉTIQUE	30.04.
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of Wee1 and Pkmyt1 Inhibition	30.04.
Repare Therapeutics Inc. Announces Directorate Changes	26.04.
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors	26.04.
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21.03.
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	15.03.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	12.03.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	03.03.
Repare Therapeutics to Participate in Two Upcoming Investor Conferences	29.02.
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	28.02.
Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	24.02.
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)	17.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Repare Therapeutics Inc.

Aktien

A2P7AV

US7602731025

RPTX

Andere Sprachen

Filter